Drug Trial News

RSS
Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

11 Jan 2011
Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

11 Jan 2011
Study supports use of telomerase inhibitors for treatment of childhood cancers

Study supports use of telomerase inhibitors for treatment of childhood cancers

11 Jan 2011
Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

Bioheart announces primary focus on completing clinical evaluation of cell therapies for heart failure

11 Jan 2011
TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

11 Jan 2011
DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

11 Jan 2011
Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

11 Jan 2011
Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

11 Jan 2011
NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

11 Jan 2011
LibiGel may be the first FDA approved product to treat HSDD in menopausal women

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

11 Jan 2011
Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

Enobia Pharma completes ENB-0040 Phase II study in juveniles with hypophosphatasia

10 Jan 2011
Celator, Cephalon extend cancer research agreement

Celator, Cephalon extend cancer research agreement

10 Jan 2011
Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

10 Jan 2011
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

10 Jan 2011
Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

10 Jan 2011
Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

10 Jan 2011
Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

10 Jan 2011
Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

10 Jan 2011
FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

10 Jan 2011
KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

10 Jan 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback